Explore the revolutionary ARX-788 antibody-drug conjugate, a precision cancer treatment targeting HER2-positive cancers with unprecedented accuracy and efficacy.
Discover how a new irreversible HER2 inhibitor acts as a precision weapon against cancer cells while sparing healthy tissue
Discover how RIG-I protein downregulates HER2 through the PI3K/Akt pathway in ovarian cancer cells, offering new therapeutic possibilities.